Discontinued — last reported Q4 '25
Cencora Acquisitions increased by 2045.0% to $4.71B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 19.6%, from $3.94B to $4.71B. Over 3 years (FY 2022 to FY 2025), Acquisitions shows an upward trend with a 212.8% CAGR.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
acquisitions| Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $62.64M | $61.52M | $0.00 | $9.66M | $0.00 | $1.41B | $0.00 | $154.00K | $0.00 | $2.31M | $22.18M | $45.28M | $9.02M | $3.94B | $56.46M | $91.41M | $219.69M | $4.71B |
| QoQ Change | — | -1.8% | -100.0% | — | -100.0% | — | -100.0% | — | -100.0% | — | +860.0% | +104.2% | -80.1% | >999% | -98.6% | +61.9% | +140.3% | >999% |
| YoY Change | — | — | — | — | -100.0% | >999% | — | -98.4% | — | -99.8% | — | >999% | — | >999% | +154.6% | +101.9% | >999% | +19.6% |